KMM-PMP

Program Description

We plan to generate genomic profiles of Asian multiple myeloma patients who receive induction chemotherapy. Multiple myeloma is a representative hematologic malignancy where targeted agents, high-dose chemotherapy and allogeneic stem cell transplantation are exploited. Also, it is well known that the prevalence of myeloma varies according to different geographic regions suggesting an ethnic difference. We are experiencing an unprecedented era of novel agents in myeloma treatment. 

However, predictive biomarkers for these various agents including proteasome inhibitors and immunomodulatory agents are not well defined and the use of these novel agents is yet to be optimized. Also, most multiple myeloma patients experience disease progression despite these treatments and there are unmet needs for medical innovation. 

To summarize, we aim to; 

1. establish predictive biomarker for anti-myeloma treatments including toxicity, and 
2. discover novel pathways for developing anti-myeloma treatments through this project.

Program Goals and Expected Outcomes

• Reveal biomarkers for novel drugs in terms of both efficacy and toxicity
• Reveal immune treatment strategy in multiple myeloma
• Reveal anti-apoptotic drug treatment strategy in multiple myeloma

What gaps in existing knowledge will be addressed by the study?

Despite recent advances in myeloma treatment, biomarkers for both efficacy and toxicity prediction are not satisfactory. This project will greatly advance precision treatment with new drugs based on biomarkers.

Program Team

Sung-Soo Yoon

Lead Investigator